Genetic Engineering and Biotechnology News

Pancreatic cancer - isometric view

Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling

Credit: Nemes Laszlo / iStock / Getty Images Plus

Panelists:

Image of Josh Wheeler, MD, PhD

Josh Wheeler, MD, PhD

Vice President, Research and Development
Genialis

Panelist

Image of Josh Wheeler, MD, PhD

Josh Wheeler, MD, PhD

Josh Wheeler, MD, PhD, is the vice president of Research and Development at Genialis with more than 15 years of experience spanning academic research, computational biology, and biotechnology. His work sits at the intersection of clinical development, translational medicine, AI and machine learning, diagnostics, and precision oncology. At Genialis, he leads clinical and research innovation strategy, biomarker and diagnostic development, clinical trial assay and regulatory strategy, and biopharma partnerships. Josh previously trained and practiced at Stanford across anatomic pathology, neuropathology, molecular diagnostics, and computational biology. He earned his MD from the University of Colorado Anschutz Medical Campus through the NIH-funded Medical Scientist Training Program and his PhD in biochemistry from the University of Colorado Boulder.

Image of Matthieu Spriet, PhD

Matthieu Spriet, PhD

Technical Specialist
Inventia Life Science

Panelist

Image of Matthieu Spriet, PhD

Matthieu Spriet, PhD

Matthieu Spriet, PhD, is a technical sales specialist at Inventia Life Science with expertise in 3D biology, biochemistry, cell signaling, oncology, and assay development. He earned his PhD in biochemistry and molecular biology from the University of Nebraska Medical Center. His thesis focused on profiling and understanding RNA expression in cholangiocarcinoma.

After graduating, Matthieu spent many years working in early-stage drug discovery, developing cell-based assays across multiple disease models, including oncology, immunology, cardiology, hepatology, and regenerative medicine. Matthieu is passionate about scientific communication and collaboration, with a focus on advancing biomedical research through advanced 3D cell models and drug discovery innovation.

Broadcast Date: 
  • Time: 

Pancreatic cancer is experiencing a renaissance in therapeutic options and improvements in patient outcomes. Accelerating therapeutic advances demands a more robust translational pipeline linking patient biology to preclinical model systems. The tumor microenvironment shapes both prognosis and therapeutic vulnerabilities, making its representation in preclinical models critical for translation.

In this GEN webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity. During the webinar, he will present Genialis Supermodel, an interpretable AI foundation model that translates tumor RNA-seq into biological states that can be compared across patients, experimental models, and Inventia’s RASTRUM platform, which enables bioprinted PDAC models with increasing microenvironmental complexity through the addition of cancer-associated fibroblasts (CAFs) and T cells.

Using pancreatic cancer as a case study, he will demonstrate how increasing microenvironmental complexity moved the bioprinted models toward distinct biological states observed in patients. You will learn how CAFs drove EMT and TGF-beta/SMAD activity with loss of classical epithelial identity, while adding immune cells produced inflammatory and interferon programs. These changes also exposed therapeutic biology not apparent in monoculture, including altered RAS/MAPK, EGFR, beta-catenin, and YAP/TEAD signaling. Key takeaways include:

  • How technologies from Genialis and Inventia provide a framework to connect patient tumor biology with experimentally tractable model systems
  • How patient-centered models generate therapeutic hypotheses that monoculture may miss

A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.

Produced with support from:

Inventia Life Science Logo